During the last decade, nine new antiepileptic drugs were approved for use by the US Food and Drug Administration. The characteristics of three of these new antiepileptic drugs—levetiracetam, oxcarbazepine, and zonisamide—are reviewed here. Their individual characteristics, including mechanism of action, efficacy, safety, and pharmacokinetics, are compared, and their effectiveness in treating specific seizure types is noted. As with all antiepileptic drugs, the efficacy, side-effect, and pharmacokinetic profiles must be matched to each individual's clinical profile to attain the maximum benefit. All three are unique and will be useful in expanding the aggregate of therapies available to clinicians treating diverse epilepsy syndromes and seizure types. This review focuses on results in adults; pediatric experience is reported in other articles in this supplement. (J Child Neurol 2002; 17:S53—S57).
Get full access to this article
View all access options for this article.
References
1.
Klitgaard H. : Levetiracetam: The preclinical profile of a new class of antiepileptic drugs?Epilepsia2001;42(Suppl 4):13—18.
2.
Noyer M., Gillard M., Matagne A., et al: The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol1995;286:137—146.
3.
Wamil AW, Schmutz M., Portet C., et al: Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures. Eur J Pharmacol1994;271:301—308.
4.
Calabresi P. , De Murtas M., Stefani A., et al: Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission. Epilepsia1995;36:990—996.
5.
Stefani A., Pisani A., De Murtas M, et al: Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia1995;36:997—1002.
6.
Suzuki S., Kawakami K., Nishimura S., et al: Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res1992;12:21—27.
7.
Wada Y., Hasegawa H., Okuda H., Yamaguchi N.: Anticonvulsant effects of zonisamide and phenytoin on seizure activity of the feline visual cortex. Brain Dev1990;12:206—210.
8.
Seino M., Naruto S., Ito T., Miyazaki H.: Other antiepileptic drugs, in Levy RH, Mattson RH, Meldrum BS (eds): Antiepileptic Drugs, 4th ed. New York, Raven1995, 1011—1024.
9.
Ito T., Hori M., Kadokawa T.: Effects of zonisamide (AD-810) on tungstic acid gel-induced thalamic generalized seizures and conjugated estrogen-induced cortical spike-wave discharges in cats. Epilepsia1986;27:367—374.
10.
Fromm GH, Shibuya T., Terrence CF: Effect of zonisamide (CI-912) on a synaptic system model. Epilepsia1987;28:673—679.
11.
Marson AG, Kadir ZA, Chadwick DW: New antiepileptic drugs: A systematic review of their efficacy and tolerability . BMJ1996;313: 1169—1174.
12.
Marson AG, Kadir ZA, Hutton JL, Chadwick DW: The new antiepileptic drugs: A systematic review of their efficacy and tolerability . Epilepsia1997;38:859—880.
13.
Grant R., Shorvon SD: Efficacy and tolerability of 1000—4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy. Epilepsy Res2000;42:89—95.
14.
Cereghino JJ, Biton V., Abou-Khalil B., et al: Levetiracetam for partial seizures: Results of a double-blind, randomized clinical trial. Neurology2000;55:236—242.
15.
Shorvon SD, Lowenthal A., Janz D., et al: Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures . Epilepsia2000;41:1179—1186.
16.
Ben-Menachem E., Falter U.: Efficacy and tolerability of levetiracetam 3000 mg in patients with refractory partial seizures: A multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia2000;41:1276—1283.
17.
Leppik IE: Levetiracetam: Clinical use, in Levy et al (eds): Antiepileptic Drugs, 5th ed. 2002. In press.
18.
Barcs G., Walker EB, Elger CE, et al: Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia2000;41:1597—1607.
19.
Privitera M. : Efficacy of levetiracetam: A review of three pivotal clinical trials. Epilepsia2001;42(Suppl 4):31—35.
20.
Smith K., Betts T., Pritchett L.: Levetiracetam, A Promising Option for the Treatment of Juvenile Myoclonic Epilepsy. Paper presented at the 4th European Congress on Epileptology, Firenze, Italy, October 7, 2000.
21.
Kasteijn-Nolst Trenite Dga, Marescaux C., Stodieck S., et al: Photosensitive epilepsy: A model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res1996;25:225—230.
22.
Genton P., Gelisse P.: Antimyoclonic effects of levetiracetam. Epil Disord2000;2:209—212.
23.
Krauss GL, Bergin A., Kramer RE, et al: Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology2001;56:411—412.
24.
Bill PA, Vigonius U., Pohlmann H., et al: A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res1997;27:195—204.
25.
Christe W., Krämer G., Vigonius U., et al: A double-blind controlled clinical trial: Oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res1997;26:451—460.
26.
Sachdeo RC, Edwards K., Hasegawa H., et al: Safety and efficacy of oxcarbazepine 1200 mg/day in patients with recent-onset partial epilepsy, abstract. Neurology1999;52(Suppl 2):A391.
27.
Schachter SC , Vazquez B., Fisher RS, et al: Oxcarbazepine: Double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology1999;52:732—737.
28.
Beydoun A., Sachdeo R., Rosenfeld WE, et al: Oxcarbazepine monotherapy for partial-onset seizures: A multicenter, double-blind, clinical trial. Neurology2000 ;54:2245—2251.
Faught E., Ayala R., Montouris G., et al: Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology2001;57:1774—1779.
31.
Leppik IE, Willmore LJ, Homan RW, et al: Efficacy and safety of zonisamide: Results of a multicenter study. Epilepsy Res1993;14:165—173.
32.
Schmidt D., Jacob R., Loiseau P., et al: Zonisamide for add-on treatment of refractory partial epilepsy: A European double blind trial. Epilepsy Res1993;15:67—73.
33.
Kyllerman M. , Ben-Menachem E.: Zonisamide for progressive myoclonus epilepsy: Long-term observations in seven patients. Epilepsy Res1998;29:109—114.
34.
Henry T., Leppik IE, Gumnit RJ, Jacobs M.: Progressive myoclonus epilepsy treated with zonisamide. Neurology1988;38:928—931.
35.
Wellington K., Goa K.: Oxcarbazepine: An update of its efficacy in the management of epilepsy. CNSDrugs2001 ;15:137—163.
36.
Dam M., Ekberg R., Loyning Y., et al: A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res1989;3:70—76.
37.
Zonegran, package insert. South San Francisco, CA: Elan Pharmaceuticals, 2000.
38.
Buchanan RA , Bockbrader HN, Chang T., Sedman AJ: Single-and multiple-dose pharmacokinetics of zonisamide. Epilepsia1996; 37(Suppl 5):172—181.
39.
Taylor C., McLean J., Brockbrader H., et al: Zonisamide, in Meldrum B and Porter R (eds): New Anticonvulsant Drugs. London: John Libbey, 1986, 277—294.
40.
Stiff DD, Zemaitis MA: Metabolism of the anticonvulsant agents zonisamide in the rat. Drug Metab Dispos1990;18:888—894.
41.
Leppik IE: Issues in the treatment of epilepsy. Epilepsia2001; 42(Suppl 4):1—6.
